A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
Clinical trial NCT05528406 · UNKNOWN
Trial details
- NCT number
- NCT05528406
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-20
- Primary completion
- 2024-10-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.